Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

380 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
JAK2(V617F) allele burden ⩾50% is associated with response to ruxolitinib in persons with MPN-associated myelofibrosis and splenomegaly requiring therapy.
Barosi G, Klersy C, Villani L, Bonetti E, Catarsi P, Poletto V, Campanelli R, Impera S, Latagliata R, Viarengo G, Carolei A, Massa M, Musso M, Crescimanno A, Gale RP, Rosti V. Barosi G, et al. Leukemia. 2016 Aug;30(8):1772-5. doi: 10.1038/leu.2016.45. Epub 2016 Feb 29. Leukemia. 2016. PMID: 26975727 Clinical Trial. No abstract available.
Functional and genetic aberrations of in vitro-cultured marrow-derived mesenchymal stromal cells of patients with classical Philadelphia-negative myeloproliferative neoplasms.
Avanzini MA, Bernardo ME, Novara F, Mantelli M, Poletto V, Villani L, Lenta E, Ingo DM, Achille V, Bonetti E, Massa M, Campanelli R, Fois G, Catarsi P, Gale RP, Moretta A, Aronica A, Maccario R, Acquafredda G, Lisini D, Zecca M, Zuffardi O, Locatelli F, Barosi G, Rosti V; AGIMM Investigators. Avanzini MA, et al. Among authors: barosi g. Leukemia. 2014 Aug;28(8):1742-5. doi: 10.1038/leu.2014.97. Epub 2014 Mar 12. Leukemia. 2014. PMID: 24618733 No abstract available.
Clinical effect of driver mutations of JAK2, CALR, or MPL in primary myelofibrosis.
Rumi E, Pietra D, Pascutto C, Guglielmelli P, Martínez-Trillos A, Casetti I, Colomer D, Pieri L, Pratcorona M, Rotunno G, Sant'Antonio E, Bellini M, Cavalloni C, Mannarelli C, Milanesi C, Boveri E, Ferretti V, Astori C, Rosti V, Cervantes F, Barosi G, Vannucchi AM, Cazzola M; Associazione Italiana per la Ricerca sul Cancro Gruppo Italiano Malattie Mieloproliferative Investigators. Rumi E, et al. Among authors: barosi g. Blood. 2014 Aug 14;124(7):1062-9. doi: 10.1182/blood-2014-05-578435. Epub 2014 Jul 1. Blood. 2014. PMID: 24986690 Free PMC article.
A randomized study of pomalidomide vs placebo in persons with myeloproliferative neoplasm-associated myelofibrosis and RBC-transfusion dependence.
Tefferi A, Al-Ali HK, Barosi G, Devos T, Gisslinger H, Jiang Q, Kiladjian JJ, Mesa R, Passamonti F, McMullin MF, Ribrag V, Schiller G, Vannucchi AM, Zhou D, Reiser D, Zhong J, Gale RP. Tefferi A, et al. Among authors: barosi g. Leukemia. 2017 Apr;31(4):896-902. doi: 10.1038/leu.2016.300. Epub 2016 Oct 24. Leukemia. 2017. PMID: 27773929 Free PMC article. Clinical Trial.
MPN-associated myelofibrosis (MPN-MF).
Mesa RA, Green A, Barosi G, Verstovsek S, Vardiman J, Gale RP. Mesa RA, et al. Among authors: barosi g. Leuk Res. 2011 Jan;35(1):12-3. doi: 10.1016/j.leukres.2010.07.019. Epub 2010 Aug 4. Leuk Res. 2011. PMID: 20684988 No abstract available.
380 results